Stock comparison
LeMaitre Vascular
Taysha Gene Therapies
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
TSHA
Taysha Gene Therapies
Market cap
$1.37B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | TSHA | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 41D | LMAT |
| Benjamin Graham | 89A | 56D | LMAT |
| Philip Fisher | 81C | 61C | LMAT |
| Peter Lynch | 67B | 5F | LMAT |
| Joel Greenblatt | 56D | 2F | LMAT |
| Charlie Munger | 68D | 57D | LMAT |
| Terry Smith | 69D | 58D | LMAT |
Side-by-side metrics
| Metric | LMAT | TSHA |
|---|---|---|
| Market cap | $2.23B | $1.37B |
| P/E (TTM) | 37.1x | - |
| EV/EBIT | 36.6x | - |
| ROIC (TTM) | 9.43% | -47.3% |
| Gross margin | 72.39% | 88.22% |
| Net margin | 24.35% | -17.38% |
| Revenue CAGR 5y | 12.75% | - |
| EPS CAGR 5y | 19.04% | - |
| Debt / Equity | 0.5x | 0.1x |
| Dividend yield | 0.84% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- ROIC (TTM)9.43%vs -47.3%+120%
- Net margin24.35%vs -17.38%+101%
- Dividend yield0.84%vs 0.0%+100%
- Market cap$2.23Bvs $1.37B+38%
TSHA leads on
- P/E (TTM)-vs 37.1x+142%
- EV/EBIT-vs 36.6x+128%
- Debt / Equity0.1xvs 0.5x+82%
- Gross margin88.22%vs 72.39%+18%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.